Category: BioTech

Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Avnet Reports Soft Sales to Western Markets, Growth in Asia

We’re maintaining our fair value estimate and moat rating for Avnet AVT after it reported third-quarter results that indicate trepidation from enterprise businesses in Western markets, but continued growth in emerging markets. Avnet generated $6.3 billion of total sales, in line with seasonality and our own expectations. Pro-forma sales to higher-margin Western markets (EMEA and Americas) declined year-overyear in both of Avnet’s segments—electronics marketing (EM) … Continue reading Avnet Reports Soft Sales to Western Markets, Growth in Asia

John MeadyLeave a comment
BioTech, Finance

Active Biotech Stock: Amgen Posts Q2 Earnings, Dominates News

Amgen (AMGN) reported second quarter 2014 earnings of $2.37 per share, well above the Consensus Estimate of $1.99 and the year-ago earnings of $1.88. Total revenues increased 11% to $5,180 million in the second quarter of 2014, beating the Consensus Estimate of $4,875 million. Including one-time items, second quarter earnings increased 22% to $2.01 per share. Second quarter total product revenues increased 8% from the … Continue reading Active Biotech Stock: Amgen Posts Q2 Earnings, Dominates News

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Ametek Delivers Earnings Growth in First Quarter

Ametek AME delivered first-quarter earnings of $0.51 per diluted share, an 11% increase versus the first quarter of 2012. While operating margin performance was ahead of pace to meet our full-year expectation, revenue growth, including acquisitions, of 7% was a bit weaker than we anticipated. Management increased the bottom end of its full-year EPS guidance from $2.07 to $2.08, resulting in a new midpoint of … Continue reading Ametek Delivers Earnings Growth in First Quarter

John MeadyLeave a comment
BioTech, Finance

Biotech Stock to Watch: Vertex Pharma. Posts Q2 Results

Vertex Pharmaceuticals Inc.’s (VRTX) second-quarter 2014 loss came in at 79 cents per share (including stock-based compensation expense), much wider than the loss of 21 cents reported in the year-ago quarter. Second quarter 2014 loss was also wider than the Consensus Estimate of a loss of 74 cents. Excluding the impact of stock-based compensation expense, second quarter 2014 loss was 61 cents per share as … Continue reading Biotech Stock to Watch: Vertex Pharma. Posts Q2 Results

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

American Electric Power Posts Flat First-Quarter Earnings

American Electric Power AEP reported $0.80 ongoing EPS for the first quarter of 2013, flat from the year-ago quarter. Management reaffirmed ongoing 2013 EPS guidance of $3.05 to $3.25. The company recently announced a $0.49 quarterly dividend, a 4.3% increase and in line with the previously announced increased targeted dividend payout ratio of 60% to 70%. We are reaffirming our 2013 EPS forecast, our $48 … Continue reading American Electric Power Posts Flat First-Quarter Earnings

John MeadyLeave a comment
BioTech, Finance

Biotech Stock Focus: Celgene Beats Q2 Estimates With Strong Showings

In an impressive piece of news on the Stock Market, Celgene (CELG) reported second-quarter 2014 earnings (including stock-based compensation expenses) of 80 cents per share, which surpassed the Market Consensus Estimate by 3 cents. The company’s earnings were 70 cents per share in the year-ago quarter. Figures have been adjusted to reflect the two-for-one stock split effective last month. Investors were not pleased with the … Continue reading Biotech Stock Focus: Celgene Beats Q2 Estimates With Strong Showings

Richard Atkins